Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
125 hedge funds and large institutions have $4.41B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 44 reducing their positions, and 13 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
33% more capital invested
Capital invested by funds: $3.3B → $4.41B (+$1.1B)
5% more funds holding
Funds holding: 119 → 125 (+6)
9% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 44
21% less call options, than puts
Call options by funds: $16.4M | Put options by funds: $20.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$110M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$17.7M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$15.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$21.8M |
| 2 |
Barclays
London,
United Kingdom
|
-$14.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$14.2M |
| 4 |
BCI
Bain Capital Investors
Boston,
Massachusetts
|
-$13.3M |
| 5 |
State Street
Boston,
Massachusetts
|
-$11.3M |
CERE Hedge Fund Activity: Q2 2023 in Review
125 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q2 2023, worth a combined $4.41B — up 33% from $3.3B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CERE positions and 13 closed out — a net gain of 6 holders — while 48 added to existing stakes and 44 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $110M. The largest seller was Federated Hermes, cutting an estimated $21.8M.
- 125 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q2 2023, up from 119 in Q1 2023.
- Funds reported $4.41B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q2 2023, up 33% quarter-over-quarter.
- 19 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q2 2023 and 13 closed out, a net change of +6 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q2 2023 was Perceptive Advisors, an estimated $110M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q2 2023 was Federated Hermes, an estimated $21.8M sold.
Based on aggregated 13F filings for Q2 2023.